A5080768333- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Gut microbiota and health
- Clostridium difficile and Clostridium perfringens research
- Immunotherapy and Immune Responses
- Autoimmune and Inflammatory Disorders Research
- Cerebral Venous Sinus Thrombosis
- Liver Diseases and Immunity
- Mycobacterium research and diagnosis
- Cytokine Signaling Pathways and Interactions
- RNA regulation and disease
- Advanced MRI Techniques and Applications
- Vagus Nerve Stimulation Research
- Drug-Induced Hepatotoxicity and Protection
- Viral Infections and Immunology Research
- Ultrasound and Hyperthermia Applications
- Vestibular and auditory disorders
- Psoriasis: Treatment and Pathogenesis
- Advanced Neuroimaging Techniques and Applications
- Gastrointestinal motility and disorders
London Health Sciences Centre
2009-2019
Western University
2009-2018
St Michaels Hospital
2016
University of British Columbia Hospital
2016
Ottawa Hospital
2016
University of Ottawa
2013-2016
Ottawa Hospital Research Institute
2016
Foothills Medical Centre
2016
Novartis (Canada)
2016
Montreal Neurological Institute and Hospital
2016
We report a natural history study of 216 patients with primary progressive (PP)- multiple sclerosis defined by at least 1 year exacerbation-free progression onset. This represents 19.8% largely population-based patient cohort having mean longitudinal follow-up 23 years. subgroup PP-multiple had age onset 38.5 years, females predominating ratio 1.3:1.0. The rate deterioration from disease was substantially more rapid than for relapsing-remitting sclerosis, median time to disability status...
The clinical features of relapses and progression largely define multiple sclerosis phenotypes. A relapsing course is followed by chronic in some 80% cases within 2 decades. relationship between these phases long-term outcome remains uncertain. We have analysed a well-studied natural history cohort with mean follow-up 25 years. For the entire cohort, median times to reach Disability Status Scale (DSS) 6, 8 10 were 12.7, 20.6 43.9 years, respectively. Among 824 attack-onset patients, great...
<h3>Objective:</h3> To examine the effects of interferon beta (IFNβ)-1b on all-cause mortality over 21 years in cohort 372 patients who participated pivotal randomized clinical trial (RCT), retaining (in analysis) original treatment-assignments. <h3>Methods:</h3> For this long-term study, primary outcome, defined before data collection, was comparison between IFNβ-1b 250 μg and placebo groups from time randomization through entire 21-year follow-up interval (intention-to-treat, log-rank test...
On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces risk conversion from first demyelinating event (also known as clinically isolated syndrome) multiple sclerosis. During period January 2009 through July 2013, randomly assigned participants who had their symptoms within previous 180 days receive either 100 mg minocycline, administered orally twice daily, or placebo. Administration placebo was continued until...
Objective: To investigate the effect of teriflunomide on efficacy and safety seasonal influenza vaccine. Methods: The 2011/2012 vaccine (containing H1N1, H3N2, B strains) was administered to patients with relapsing forms multiple sclerosis (RMS) treated for ≥6 months 7 mg (n = 41) or 14 41), interferon-β-1 (IFN-β-1; n 46). primary endpoint proportion strain–specific antibody titers ≥40, 28 days postvaccination. Results: More than 90% achieved postvaccination ≥40 H1N1 in all groups. For were...
To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or a short delay.Participants in BENEFIT (Betaferon/Betaseron Newly Emerging MS Initial Treatment) were randomly assigned to receive (early treatment) placebo (delayed treatment). After conversion definite multiple sclerosis (CDMS) 2 years, on could switch another treatment. Eleven years randomization, reassessed.Two hundred seventy-eight (59.4%) of the original 468 (71.3%...
Infusion of PDA-001, a preparation mesenchymal-like cells derived from full-term human placenta, is new approach in the treatment patients with multiple sclerosis.This safety study aimed to rule out possibility paradoxical exacerbation disease activity by PDA-001 was phase 1b, multicenter, randomized, double-blind, placebo-controlled, 2-dose ranging including relapsing-remitting sclerosis or secondary progressive sclerosis. The conducted at 6 sites United States and 2 Canada. Patients were...
<h3>Importance</h3> Intravenous (IV) administration of corticosteroids is the standard care in treatment acute optic neuritis. However, it uncertain whether a bioequivalent dose corticosteroid administered orally, which may be more cost-efficient and convenient for patients, as effective IV <h3>Objective</h3> To determine recovery vision following neuritis with high-dose superior to that an oral corticosteroid. <h3>Design, Setting, Participants</h3> This single-blind (participants unblinded)...
Patients with MS have an altered gut microbiota compared to healthy individuals, as well elevated small intestinal permeability, which may be contributing the development and progression of disease.We sought investigate if fecal transplantation was safe tolerable in patients it could improve abnormal permeability.Nine were recruited provided monthly FMTs for up six months. The primary outcome investigated change peripheral blood cytokine concentrations. secondary outcomes composition, safety...
Classifications of multiple sclerosis subtypes have been largely based on clinical phenomenology. Nevertheless, definitions relapse, remission and progression imprecise. Recently an international consensus group, as part a reclassification disease subtypes, recommended dropping the term 'relapsing-progressive' (RP) retaining 'progressive-relapsing' (PR) sclerosis. The 'RP' had applied when early course combined both relapses was believed to identify some patients with worse than average...
Aim An exploratory study of the relationship between cumulative exposure to subcutaneous (sc) interferon (IFN) β-1a treatment and other possible prognostic factors with long-term clinical outcomes in relapsing–remitting multiple sclerosis (RRMS). Methods Patients original PRISMS were invited a single follow-up visit 15 years after initial randomisation (PRISMS-15). Outcomes over compared lowest highest quartile sc IFN dose groups, according total time receiving as continuous variable per 5...
<h3>Objective:</h3> To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on MRI lesion activity and load, atrophy, magnetization transfer ratio (MTR) measures from Comparator an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (CONFIRM) study. <h3>Methods:</h3> CONFIRM was a 2-year, placebo-controlled study efficacy safety DMF 240 mg twice (BID) or 3 times daily (TID) 1,417 patients with relapsing-remitting multiple sclerosis...
To evaluate the potential of quantitative susceptibility (QS) and R2* mapping as surrogate biomarkers clinically relevant, age-adjusted demyelination iron deposition in multiple sclerosis (MS).All study participants gave written informed consent, was approved by institutional review board. Quantitative maps magnetic resonance imaging parameters (R2* QS) were computed for 25 patients with either isolated syndrome (CIS) or relapsing-remitting MS, well 15 age- sex-matched control subjects...
<h3>Objective:</h3> To characterize effects of alemtuzumab treatment on measures disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) inadequate response (≥1 relapse) to prior therapy. <h3>Methods:</h3> Comparison Alemtuzumab and Rebif Efficacy Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy safety 12 mg subcutaneous interferon-β-1a (SC IFN-β-1a) 44 μg RRMS. Prespecified...
There are few studies reporting multiple sclerosis prevalence rates in the Buenos Aires region, Argentina (latitude 34°S) (between 12–18.5/100 000 inhabitants), and no have been performed larger region between parallels 36° 55°S. The aim of this study is to determine clinical features residents Argentine Patagonia. Four cities from were selected for study, giving a sample population 417 666 inhabitants (~24% total Patagonia population). 1 st March 2002 was determined as day. Patients...
Approximately 85% of multiple sclerosis (MS) cases begin as clinically isolated syndromes (CIS). Results from the Controlled High-Risk Subjects Avonex ® Multiple Sclerosis Prevention Study (CHAMPS) demonstrated that, in patients with CIS, treatment intramuscular (IM) interferon beta-1a (IFNβ-1a) 30 μg once weekly delayed conversion to definite MS (CDMS) total population and subgroups based on presenting baseline magnetic resonance imaging (MRI) characteristics. Changes clinical MRI risk...
Compared with controls, multiple sclerosis (MS) patients die, on average, 7-14 years prematurely. Previously, we reported that, 21 after their participation in the pivotal randomised, controlled trial (RCT) of interferon β-1b, mortality was reduced by 46-47% two groups who received active therapy during RCT. To determine whether excessive deaths observed placebo-treated due to MS-related causes, analysed causes-of-death (CODs) these three, patient cohorts.Long-term follow-up (LTF) RCT...